Atrion (ATRI) 10-K 13 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 17, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	ATRI
Entity Registrant Name	ATRION CORP
Entity Central Index Key	701288
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		1,872,848
Entity Public Float			$498,111,374

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenues	$140,762	$131,993	$119,062
Cost of Goods Sold	72,244	68,931	62,922
Gross Profit	68,518	63,062	56,140
Operating Expenses:
Selling	6,210	6,218	5,694
General and administrative	16,205	14,612	13,054
Research and development	5,286	4,288	3,766
Operating Expenses, Total	27,701	25,118	22,514
Operating Income	40,817	37,944	33,626
Interest Income	1,191	1,313	1,447
Other Income, net	13	8	2
Income before Provision for Income Taxes	42,021	39,265	35,075
Provision for Income Taxes	-14,213	-12,683	-11,446
Net Income	$27,808	$26,582	$23,629
Net Income Per Basic Share	$14.20	$13.22	$11.72
Weighted Average Basic Shares Outstanding	1,958	2,010	2,016
Net Income Per Diluted Share	$14.08	$13.18	$11.66
Weighted Average Diluted Shares Outstanding	1,975	2,017	2,027
Dividends Per Common Share	$2.78	$2.40	$12.10

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements Of Comprehensive Income
Net Income	$6,040	$7,685	$6,882	$7,201	$5,768	$7,673	$6,506	$6,635	$27,808	$26,582	$23,629
Other Comprehensive loss, net of tax: Unrealized loss on investments, net of tax benefit of $131 in 2014									-245	0	0
Comprehensive Income									$27,563	$26,582	$23,629

CONSOLIDATED_BALANCE_SHEET

CONSOLIDATED BALANCE SHEET (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$20,775	$28,559
Short-term investments	3,084	18,351
Accounts receivable, net of allowance for doubtful accounts of $22 and $86 in 2014 and 2013, respectively	16,962	14,164
Inventories	28,022	26,266
Prepaid expenses and other current assets	4,720	1,603
Deferred income taxes	573	1,376
Total Current Assets	74,136	90,319
Long-term investments	21,760	10,069
Property, Plant and Equipment	142,171	130,504
Less accumulated depreciation and amortization	79,655	72,176
Property plant and equipment net	62,516	58,328
Other Assets and Deferred Charges:
Patents and licenses, net of accumulated amortization of $11,301 and $11,032 in 2014 and 2013, respectively	2,538	2,808
Goodwill	9,730	9,730
Other	834	812
Prepaid Expense and Other Assets, Noncurrent, Total	13,102	13,350
Total Assets	171,514	172,066
Current Liabilities:
Accounts payable	4,529	4,088
Accrued liabilities	4,950	4,423
Accrued income and other taxes	457	853
Total Current Liabilities	9,936	9,364
Line of credit	0	0
Other Liabilities and Deferred Credits:
Deferred income taxes	11,129	12,062
Other	879	1,646
Liabilities Noncurrent	12,008	13,708
Total Liabilities	21,944	23,072
Commitments and Contingencies
Stockholders' Equity:
Common stock, par value $.10 per share, authorized 10,000 shares, issued 3,420 shares	342	342
Additional paid-in capital	33,940	31,592
Accumulated other comprehensive loss	-245	0
Retained earnings	196,706	174,362
Treasury shares, 1,507 shares in 2014 and 1,435 shares in 2013, at cost	-81,173	-57,302
Total Stockholders' Equity	149,570	148,994
Total Liabilities and Stockholders' Equity	$171,514	$172,066

CONSOLIDATED_BALANCE_SHEET_Par

CONSOLIDATED BALANCE SHEET (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$22	$86
Patents and licenses, accumulated amortization	$11,301	$11,032
Common stock, par value	$0.10	$0.10
Common stock, authorized	10,000	10,000
Common stock, issued	3,420	3,420
Treasury shares, shares	1,507	1,435

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows From Operating Activities:
Net Income	$27,808	$26,582	$23,629
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	8,723	8,592	7,610
Deferred income taxes	2	-923	1,462
Stock-based compensation	2,209	1,586	1,482
Net change in accrued interest, premiums, and discounts on investments	340	556	817
Other	29	30	0
Net Cash Provided By Used In Operating Activities Before Changes In Operating Capital, Total	39,111	36,423	35,000
Changes in operating assets and liabilities:
Accounts receivable	-2,798	-1,110	-1,831
Inventories	-1,756	-2,487	803
Prepaid expenses and other current assets	-3,117	1,507	-797
Other non-current assets	-22	-17	-77
Accounts payable and accrued liabilities	968	1,768	-2,465
Accrued income and other taxes	-396	388	-370
Other non-current liabilities	-767	104	-894
Net Cash Provided by (Used in) Operating Activities, Total	31,223	36,576	29,369
Cash Flows From Investing Activities:
Property, plant and equipment additions	-12,671	-7,503	-10,347
Purchase of patents	0	-2,150	0
Purchase of investments	-33,115	0	-26,566
Proceeds from maturities of investments	35,975	7,639	19,750
Net Cash Provided by (Used in) Investing Activities, Total	-9,811	-2,014	-17,163
Cash Flows From Financing Activities:
Exercise of stock options	0	0	731
Shares tendered for employees' withholding taxes on stock-based compensation	-376	0	-1,136
Tax benefit related to stock-based compensation	168	15	1,412
Purchase of treasury stock	-23,556	-9,196	-5,344
Dividends paid	-5,432	-4,821	-24,460
Net Cash Provided by (Used in) Financing Activities, Total	-29,196	-14,002	-28,797
Net change in cash and cash equivalents	-7,784	20,560	-16,591
Cash and cash equivalents, beginning of year	28,559	7,999	24,590
Cash and cash equivalents, end of year	20,775	28,559	7,999
Cash paid for:
Income taxes	$17,475	$8,036	$10,357

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (USD $)	Common Stock	Treasury Stock	Additional Paid-In Capital	Other Comprehensive Income / Loss	Retained Earnings	Total
In Thousands, except Share data
Beginning Balances at Dec. 31, 2011	$342	($40,898)	$25,452		$153,618	$138,514
Beginning Balances (in shares) at Dec. 31, 2011	2,016	1,404
Net Income					23,629	23,629
Tax benefit from stock-based compensation			1,412			1,412
Stock-based compensation transactions (in shares)	41	-41
Stock-based compensation transactions		368	3,134			3,502
Shares surrendered in stock transactions (in shares)	-9	9
Shares surrendered in stock transactions		-2,268				-2,268
Purchase of treasury stock (in shares)	-27	27
Purchase of treasury stock		-5,344				-5,344
Dividends					-24,617	-24,617
Ending Balances at Dec. 31, 2012	342	-48,142	29,998		152,630	134,828
Ending Balances (in shares) at Dec. 31, 2012	2,021	1,399
Net Income					26,582	26,582
Tax benefit from stock-based compensation			15			15
Stock-based compensation transactions (in shares)	1	-1
Stock-based compensation transactions		36	1,579			1,615
Purchase of treasury stock (in shares)	-37	37
Purchase of treasury stock		-9,196				-9,196
Dividends					-4,850	-4,850
Ending Balances at Dec. 31, 2013	342	-57,302	31,592		174,362	148,994
Ending Balances (in shares) at Dec. 31, 2013	1,985	1,435
Net Income					27,808	27,808
Other comprehensive income				-245		-245
Tax benefit from stock-based compensation			168			168
Stock-based compensation transactions (in shares)	3	-3
Stock-based compensation transactions		61	2,180			2,241
Shares surrendered in stock transactions (in shares)	-1	1
Shares surrendered in stock transactions		-376				-376
Purchase of treasury stock (in shares)	-74	74
Purchase of treasury stock		-23,556				-23,556
Ending Balances at Dec. 31, 2014	$342	($81,173)	$33,940	($245)	$196,706	$149,570
Ending Balances (in shares) at Dec. 31, 2014	1,913	1,507

1_Summary_of_Significant_Accou

1. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Atrion Corporation and its subsidiaries (“we,” “our,” “us,” “Atrion” or the “Company”) develop and manufacture products primarily for medical applications. We market our products throughout the United States and internationally.  Our customers include hospitals, distributors, and other manufacturers.  Atrion Corporation’s principal subsidiaries through which these operations are conducted are Atrion Medical Products, Inc., Halkey-Roberts Corporation and Quest Medical, Inc.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Atrion Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
	Cash and Cash Equivalents and Investments
	Cash equivalents include cash on hand and in the bank as well as money market accounts and debt securities with maturities at the time of purchase of 90 days or less.
	Our investments consist of taxable corporate and United States government agency bonds and equity securities. We classify our investment securities in one of three categories: held-to-maturity, trading, or available-for-sale. Securities that we have the positive intent and ability to hold to maturity are reported at amortized cost and classified as held-to-maturity securities.  If we do not have the intent and ability to hold a security to maturity, we report the investment as available-for-sale securities.  We report available-for-sale securities at fair value with unrealized gains and, to the extent deemed temporary, unrealized losses recorded in stockholders’ equity as accumulated other comprehensive loss.  We consider investments which will mature in the next 12 months as current assets. The remaining investments are considered non-current assets including our investment in equity securities which we intend to hold longer than 12 months. We periodically evaluate our investments for impairment. We do not believe any unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence as of December 31, 2014.
	The components of the Company’s cash and cash equivalents and our short and long-term investments as of December 31, 2014 and 2013 are as follows (in thousands):
		2014		2013
	Cash and cash equivalents::
	Cash deposits	$	14,572	$	25,958
	Money market funds		6,203		2,601
	Total cash and cash equivalents	$	20,775	$	28,559
	Short-term investments:
	Corporate bonds (held-to-maturity)	$	3,084	$	18,351
	Total short-term investments	$	3,084	$	18,351
	Long-term investments:
	Corporate bonds (held-to-maturity)	$	10,028	$	10,069
	US government agency bonds (held-to-maturity)		8,400		--
	Equity securities (available-for-sale)		3,332		--
	Total long term investments	$	21,760	$	10,069
	Total cash, cash equivalents and short and long-term investments	$	45,619	$	56,979
	Trade Receivables
	Trade accounts receivable are recorded at the original sales price to the customer.  We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments.  On an ongoing basis, the collectability of accounts receivable is assessed based upon historical collection trends, current economic factors and the assessment of the collectability of specific accounts.  We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with appropriate Company personnel and with the customers directly.  Accounts are written off when we determine the receivable will not be collected.
	Inventories
	Inventories are stated at the lower of cost (including materials, direct labor and applicable overhead) or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventory (in thousands):
		December 31,
		2014		2013
	Raw materials	$	12,575	$	10,744
	Work in process		5,600		6,246
	Finished goods		9,847		9,276
	Total inventories	$	28,022	$	26,266
	Accounts Payable
	We reflect disbursements as trade accounts payable until such time as payments are presented to our bank for payment. At December 31, 2014 and 2013, disbursements totaling approximately $613,000 and $443,000, respectively, had not been presented for payment to our bank.
	Income Taxes
	We account for income taxes utilizing Accounting Standards Codification (ASC) 740, Income Taxes , or ASC 740.  ASC 740 requires the asset and liability method for the recording of deferred income taxes, whereby deferred tax assets and liabilities are recognized based on the tax effects of temporary differences between the financial statement and the tax bases of assets and liabilities, as measured at current enacted tax rates. When appropriate, we evaluate the need for a valuation allowance to reduce deferred tax assets.
	ASC 740 also requires the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attributes of income tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more-likely-than-not of being sustained.
	Our uncertain tax positions are recorded as “Other non-current liabilities.” We classify interest expense on underpayments of income taxes and accrued penalties related to unrecognized tax benefits in the income tax provision.
	Property, Plant and Equipment
	Property, plant and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Additions and improvements are capitalized, including all material, labor and engineering costs to design, install or improve the asset. Expenditures for repairs and maintenance are charged to expense as incurred. The following table represents a summary of property, plant and equipment at original cost (in thousands):
		December 31,				Useful
		2014		2013		Lives
	Land	$	5,260	$	5,260		—
	Buildings		31,751		31,314	30-40 yrs
	Machinery and equipment		105,160		93,930	3-15 yrs
	Total property, plant and equipment	$	142,171	$	130,504
	Depreciation expense of $8,454,000, $8,413,000 and $7,448,000 was recorded for the years ended December 31, 2014, 2013 and 2012, respectively. Depreciation expense is recorded in either cost of goods sold or operating expenses based on the associated assets’ usage.
	Patents and Licenses
	Costs for patents and licenses acquired are determined at acquisition date. Patents and licenses are amortized over the useful lives of the individual patents and licenses, which are from 7 to 20 years. Patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.
	Goodwill
	Goodwill represents the excess of cost over the fair value of tangible and identifiable intangible net assets acquired.  Annual impairment testing for goodwill is done using a qualitative assessment on goodwill impairment to determine whether it is necessary to perform the two-step goodwill impairment test.  Goodwill is also reviewed whenever events or changes in circumstances indicate a change in value may have occurred.  We have identified three reporting units where goodwill was recorded for purposes of testing goodwill impairment annually: (1) Atrion Medical Products, Inc., (2) Halkey-Roberts Corporation and (3) Quest Medical, Inc.  The total carrying amount of goodwill in each of the years ended December 31, 2014, 2013 and 2012 was $9,730,000. Our evaluation of goodwill during each year resulted in no impairment losses.
	Current Accrued Liabilities
	The items comprising current accrued liabilities are as follows (in thousands):
		December 31,
		2014		2013
	Accrued payroll and related expenses	$	4,240	$	3,711
	Accrued vacation		219		229
	Other accrued liabilities		491		483
	Total accrued liabilities	$	4,950	$	4,423
	Revenues
	We recognize revenue when our products are shipped to our customers, provided an arrangement exists, the fee is fixed and determinable and collectability is reasonably assured. All risks and rewards of ownership pass to the customer upon shipment. Net sales represent gross sales invoiced to customers, less certain related charges, including discounts, returns and other allowances. Revenues are recorded exclusive of sales and similar taxes. Returns, discounts and other allowances have been insignificant historically.
	Shipping and Handling Policy
	Shipping and handling fees charged to customers are reported as revenue and all shipping and handling costs incurred related to products sold are reported as cost of goods sold.
Research and Development Costs
Research and development costs relating to the development of new products and improvements of existing products are expensed as incurred.
Stock-Based Compensation
We have stock-based compensation plans covering certain of our officers, directors and key employees. As explained in detail in Note 8, we account for stock-based compensation utilizing the fair value recognition provisions of ASC 718, Compensation-Stock Compensation, or ASC 718.
New Accounting Pronouncements
From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board, or FASB, or other standards setting bodies, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.
Fair Value Measurements
Accounting standards use a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists therefore requiring an entity to develop its own assumptions.
As of December 31, 2014 and 2013, we held certain investments in corporate and government debt securities as well as certain equity securities. These investments are all considered Level 2 assets and the fair value of our investments were estimated using recently executed transactions and market price quotations (see Note 2).
The carrying values of our other financial instruments including cash and cash equivalents, money market accounts, accounts receivable, accounts payable, accrued liabilities, and accrued income and other taxes approximated fair value due to their liquid and short-term nature.
Concentration of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable.
Our cash and cash equivalents are held in accounts with financial institutions that we believe are creditworthy. Certain of these amounts at times may exceed federally-insured limits. At December 31, 2014, approximately 91% of our cash and cash equivalents were uninsured. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds.
We have investments in United States government agency securities and corporate bonds. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer and otherwise. Approximately 24% of our aggregate fixed-income investments are below investment grade. These securities have a higher degree of credit or default risk and a greater exposure to credit risk and may be less liquid in times of economic weakness or market disruptions.
For accounts receivable, we perform ongoing credit evaluations of our customers’ financial condition and generally do not require collateral.  We maintain reserves for possible credit losses.  As of December 31, 2014 and 2013, we had allowances for doubtful accounts of approximately $22,000 and $86,000, respectively.  The carrying amount of the receivables approximates their fair value. Our customer that generates our largest revenues accounted for 6.5%, 8.2% and 16.3% of accounts receivable as of December 31, 2014, 2013 and 2012, respectively.  No other customer exceeded 10% of our accounts receivable as of December 31, 2014, 2013 or 2012.

2_Investments

2. Investments	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Investments	As of December 31, 2014 and 2013, we held certain investments that were required to be measured for disclosure purposes at fair value on a recurring basis. These investments were considered Level 2 investments. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets including our investment in equity securities which we intend to hold longer than 12 months.
	The amortized cost and fair value of our investments that are being accounted for as held-to-maturity securities, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands):
				Gross Unrealized
		Cost		Gains		Losses			Fair value
	As of December 31, 2014:
	Short-term Investments:
	Corporate bonds	$	3,084	$	--	$	(6	)	$	3,078
	Long-term Investments:
	Corporate and government bonds	$	18,428	$	21	$	(292	)	$	18,157
	As of December 31, 2013:
	Short-term Investments:
	Corporate bonds	$	18,351	$	234	$	—		$	18,585
	Long-term Investments:
	Corporate bonds	$	10,069	$	285	$	—		$	10,354
	At December 31, 2014, the length of time until maturity of these securities ranged from three and a half months to 58 months. None of the above investments has been in a loss position for more than 12 months.
	The cost and fair value of our investments that are being accounted for as available-for-sale securities, and the related gross unrealized loss reflected in accumulated other comprehensive loss, were as follows as of the dates shown below (in thousands):
				Gross Unrealized
		Cost		Gains		Losses			Fair value
	As of December 31, 2014:
	Long-term Investments:
	Equity investments	$	3,708	$	--	$	(376	)	$	3,332

3_Patents_and_Licenses

3. Patents and Licenses	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and Licenses	Purchased patents and licenses paid for the use of other entities’ patents are amortized over the useful life of the patent or license.  The following tables provide information regarding patents and licenses (dollars in thousands):
	31-Dec-14								31-Dec-13
	Weighted Average				Gross				Weighted Average		Gross
	Original Life				Carrying		Accumulated		Original Life		Carrying		Accumulated
	(years)				Amount		Amortization		(years)		Amount		Amortization
		15.67			$	13,840	$	11,302		15.67	$	13,840	$	11,032
	Aggregate amortization expense for patents and licenses was $269,000 for 2014, $179,000 for 2013 and $162,000 for 2012.  Estimated future amortization expense for each of the years set forth below ending December 31 is as follows (in thousands):
	2015		$	269
	2016		$	269
	2017		$	173
	2018		$	141
	2019		$	141

4_Line_of_Credit

4. Line of Credit	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Line of Credit	We have a $40.0 million revolving credit facility with a money center bank pursuant to which the lender is obligated to make advances until October 1, 2016. The credit facility is secured by substantially all our inventories, equipment and accounts receivable. Interest under the credit facility is assessed at 30-day, 60-day or 90-day LIBOR, as selected by us, plus one percent (1.16 percent at December 31, 2014) and is payable monthly. We had no outstanding borrowings under the credit facility at December 31, 2014 or 2013.  At any time during the term, we may convert any or all outstanding amounts under the credit facility to a term loan with a maturity of two years. Our ability to borrow funds under the credit facility from time to time is contingent on meeting certain covenants in the loan agreement, the most restrictive of which is the ratio of total debt to earnings before interest, income tax, depreciation and amortization.  At December 31, 2014, we were in compliance with all of those covenants.

5_Income_Taxes

5. Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	The items comprising income tax expense are as follows (in thousands):
				Year ended December 31,
				2014				2013				2012
	Current	— Federal		$	12,626			$	12,541			$	8,934
		— State			1,585				1,065				1,050
					14,211				13,606				9,984
	Deferred	— Federal			31				(1,063	)			1,363
		— State			(29	)			140				99
					2				(923	)			1,462
	Total income tax expense			$	14,213			$	12,683			$	11,446
	Temporary differences and carryforwards which have given rise to deferred income tax assets and liabilities as of December 31, 2014 and 2013 are as follows (in thousands):
			2014				2013
	Deferred tax assets:
	Benefit plans		$	1,535			$	1,590
	Inventories			483				525
	Other			158				37
	Total deferred tax assets		$	2,176			$	2,152
	Deferred tax liabilities:
	Property, plant and equipment		$	9,648			$	9,716
	Patents and goodwill			2,926				2,956
	Other			158				166
	Total deferred tax liabilities		$	12,732			$	12,838
	Net deferred tax liability		$	10,556			$	10,686
	Balance Sheet classification:
	Non-current deferred income tax liability		$	11,129			$	12,062
	Current deferred income tax asset			573				1,376
	Net deferred tax liability		$	10,556			$	10,686
	Total income tax expense differs from the amount that would be provided by applying the statutory federal income tax rate to pretax earnings as illustrated below (in thousands):
			Year ended December 31,
			2014				2013				2012
	Income tax expense at the statutory federal income tax rate		$	14,707			$	13,743			$	12,276
	Increase (decrease) resulting from:
	State income taxes			934				770				747
	Section 199 manufacturing deduction			(1,290	)			(1,307	)			(949	)
	Other, net			(138	)			(523	)			(628	)
	Total income tax expense		$	14,213			$	12,683			$	11,446
	A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits as required by ASC 740 is as follows (in thousands):
	Gross unrecognized tax benefits at January 1, 2012		$	1,261
	Increase in tax positions for prior years			19
	Increase in tax positions for current year			0
	Decrease due to settlement with taxing authorities			(641	)
	Lapse in statutes of limitation			(98	)
	Gross unrecognized tax benefits at December 31, 2012		$	541
	Increase in tax positions for prior years			11
	Increase in tax positions for current year			0
	Lapse in statutes of limitation			(206	)
	Gross unrecognized tax benefits at December 31, 2013		$	346
	Increase in tax positions for prior years			6
	Increase in tax positions for current year			0
	Lapse in statutes of limitation			(223	)
	Gross unrecognized tax benefits at December 31, 2014		$	129
	As of December 31, 2014 all of the unrecognized tax benefits, which were comprised of uncertain tax positions, would impact the effective tax rate if recognized. Unrecognized tax benefits that are affected by statutes of limitation that expire within the next 12 months are immaterial.
	We are subject to United States federal income tax as well as to income tax of multiple state jurisdictions.  We have concluded all United States federal income tax matters for years through 2010.  In January 2009, the Internal Revenue Service, or IRS, began examining certain of our United States federal income tax returns for 2006, 2007 and 2008. This audit was favorably concluded in the third quarter of 2012 when the IRS appeals group allowed 100% of the tax credits claimed for our R&D expenditures during those years. Our unrecognized tax benefits were reduced at that time on the basis of this favorable settlement in the amount of approximately $641,000. All material state and local income tax matters have been concluded for years through 2010.
	We recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The liability for unrecognized tax benefits included accrued interest of $9,000, $21,000 and $26,000 at December 31, 2014, 2013 and 2012, respectively. Tax expense for the year ended December 31, 2014, 2013 and 2012 included a net interest benefit of $12,000, $5,400 and $51,000, respectively.

6_Stockholders_Equity

6. Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	Our Board of Directors has at various times authorized repurchases of our stock in open-market or privately-negotiated transactions at such times and at such prices as management may from time to time determine. On August 16, 2011, our Board of Directors adopted a new stock repurchase program pursuant to which we can repurchase up to 200,000 shares of our common stock from time to time in open market or privately-negotiated transactions. This stock repurchase program has no expiration date but may be terminated by the Board of Directors at any time. As of December 31, 2014, 54,026 shares remained available for repurchase under this program. We repurchased 74,746, 36,666 and 26,562 shares under the program during 2014, 2013 and 2012, respectively.
	We have increased our quarterly cash dividend payments in September of each of the past three years. The quarterly dividend was increased to $.56 per share in September 2012, to $.64 per share in September 2013 and to $.75 per share in September 2014.  On December 10, 2012 we also paid a special cash dividend to stockholders of $10.00 per share. Holders of stock units earned non-cash dividends of $33,000 in 2014, $29,000 in 2013 and $157,000 in 2012.
	We have a Rights Plan which is intended to protect the interests of stockholders in the event of a hostile attempt to take over the Company.  The rights, which are not presently exercisable and do not have any voting powers, represent the right of our stockholders to purchase at a substantial discount, upon the occurrence of certain events, shares of our common stock or of an acquiring company involved in a business combination with us.  This plan, which was adopted in August 2006, expires in August 2016.

7_Income_Per_Share

7. Income Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Income Per Share	The following is the computation of basic and diluted income per share:
		Year ended December 31,
		2014		2013		2012
		(In thousands, except per share amounts)
	Net Income	$	27,808	$	26,582	$	23,629
	Weighted average basic shares outstanding		1,958		2,010		2,016
	Add:  Effect of dilutive securities		17		7		11
	Weighted average diluted shares outstanding		1,975		2,017		2,027
	Net Income per share
	Basic	$	14.2	$	13.22	$	11.72
	Diluted	$	14.08	$	13.18	$	11.66
	As required by ASC 260, Earnings per Share, unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are considered participating securities and, therefore, are included in the computation of basic income per share pursuant to the two-class method.
	Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method.  Dilutive securities representing eight and 4,344 shares of common stock for the years ended December 31, 2014 and December 31, 2013, respectively, were excluded from the computation of weighted average diluted shares outstanding because their effect would have been anti-dilutive

8_Stock_Plans

8. Stock Plans	12 Months Ended
	Dec. 31, 2014
Compensation Related Costs [Abstract]
Stock Plans	At December 31, 2014, we had three stock-based compensation plans which are described more fully below. We account for our plans under ASC 718, and the disclosures that follow are based on applying ASC 718. ASC 718 requires that cash flows from the use of stock-based compensation resulting from tax benefits in excess of recognized compensation cost (excess tax benefits) be classified as financing cash flows. We recorded $168,000, $15,000 and $1,412,000 of such excess tax benefits as financing cash flows in 2014, 2013 and 2012, respectively.
	Our Amended and Restated 2006 Equity Incentive Plan, or 2006 Plan, provides for awards to key employees, non-employee directors and consultants of incentive and nonqualified stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance shares and other stock-based awards. Under the 2006 Plan, 200,000 shares, in the aggregate, of common stock have been reserved for awards. The purchase price of shares issued on the exercise of options must be at least equal to the fair market value of such shares on the date of grant.  The options granted become exercisable and expire as determined by the Compensation Committee.  As of December 31, 2014, there remained 52,751 shares for future stock-based awards under the 2006 Plan.
	In May 2007, we adopted our Deferred Compensation Plan for Non-Employee Directors (as amended, the “Deferred Compensation Plan”), and 2,500 shares of our common stock were initially reserved for issuance thereunder. This plan allows our non-employee directors to elect to receive stock units in lieu of all or part of the cash fees they are receiving for their services as directors.  On the first business day of each calendar year, each participating non-employee director is credited with a number of stock units determined on the basis of the foregone cash fees and the closing price of our common stock on the next preceding date on which shares of our stock were traded.  The stock units are converted to shares of our common stock on a one-for-one basis at a future date as elected in advance by the director, but no later than the January following the year in which the director ceases to serve on the Board of Directors, and the shares are delivered to the director.   As of December 31, 2014, there remained 1,599 shares of common stock reserved for issuance upon the conversion of stock units which may be credited in the future to non-employee directors.
	In May 2007, we also adopted our Non-Employee Director Stock Purchase Plan, (as amended, the “Director Stock Purchase Plan”), and 2,500 shares of our common stock were initially reserved for issuance thereunder. Under this plan, our non-employee directors may elect to receive on the first business day of the calendar year fully-vested stock and restricted stock in lieu of some or all of their fees payable to them during such year. The foregone fees are converted into shares of fully-vested stock and restricted stock on the first business day of such calendar year based on the closing price of our common stock on the next preceding date on which shares of our stock were traded. The restricted stock vests in equal amounts on the first day of the next three succeeding calendar quarters provided the non-employee director is then serving on our Board of Directors. As of December 31, 2014, there remained 1,126 shares reserved for issuance under such plan.
	A summary of stock option transactions for the year ended December 31, 2014 is presented below:
	Options	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term
	Outstanding at December 31, 2013		50,000		$	204.76
	Granted		--			--
	Exercised		--			--
	Outstanding at December 31, 2014		50,000		$	204.76	3.9 years
	Exercisable at December 31, 2014		25,000		$	200.1	3.8 years
	All nonvested options outstanding at December 31, 2014 are expected to vest.  We estimate the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. None of our grants includes performance-based or market-based vesting conditions.  The expected life represents the period that our stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. The fair value of stock-based payments, funded with options, is valued using the Black-Scholes valuation method with a volatility factor based on our historical stock trading history. We base the risk-free interest rate using the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury securities with an equivalent term. We base the dividend yield used in the Black-Scholes valuation method on our dividend history.
	There were no options granted in 2014 or 2013.  The fair value for the options granted in 2012 was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:
		2014			2013			2012
	Risk-free interest rate		--			--			0.5	%
	Dividend yield		--			--			1	%
	Volatility factor		--			--			25	%
	Expected life		--			--		5 years
	The weighted average grant date fair value of the options granted in 2012 was $40.38. The total intrinsic value of options exercised during 2012 was $3.1 million. There were no options exercised in 2014 and 2013.  The total intrinsic values of options outstanding and options currently exercisable at December 31, 2014, were $6.8 million and $3.5 million, respectively.
	During 2014, 1,400 shares of restricted stock were awarded under the 2006 Plan.  Under the terms of our restricted stock awards, the restrictions usually lapse over a five-year period, but the 2014 grant was vested over a four-month period ended September 30, 2014. During the vesting period, holders of restricted stock have voting rights and earn dividends, but the shares may not be sold, assigned, transferred, pledged or otherwise encumbered. Nonvested shares are generally forfeited on termination of employment unless otherwise provided in the participant’s employment agreement or the termination is in connection with a change in control.  A summary of changes in nonvested restricted stock for the year ended December 31, 2014 is presented below:
	Nonvested Shares	Shares			Weighted Average Award Date Fair Value Per Share
	Restricted stock at December 31, 2013		10,500		$	208.09
	Granted in 2014		1,400		$	315.24
	Vested in 2014		(4,400	)	$	239.91
	Restricted stock at December 31, 2014		7,500		$	209.42
	All shares of nonvested restricted stock outstanding at December 31, 2014 are expected to vest. The total fair value of restricted stock vested during 2014, 2013 and 2012 was $1,372,000, $633,000 and $559,000, respectively.
	During 2014, restricted stock units were awarded to certain employees under the 2006 Plan.  All of our restricted stock units are convertible to shares of stock on a one-for-one basis when the restrictions lapse, which is generally after a five-year period. Nonvested stock units are generally forfeited on termination of employment unless the termination is in connection with a change in control. During the vesting period, holders of all restricted stock units earn dividends in the form of additional units.   During 2014, one non-employee director elected to receive stock units in lieu of a portion of his cash fees for his services as a member of the Board of Directors.
	A summary of changes in stock units for the year ended December 31, 2014, is presented below:
	Nonvested Stock Units	Restricted Stock Units			Weighted Average Award Date Fair Value Per Unit			Director’s Stock Units			Weighted Average Award Date Fair Value Per Unit
	Nonvested at December 31, 2013		12,904		$	196.35			--
	Granted		2,785		$	316.55			28		$	299.21
	Vested		(831	)	$	126.18			(28	)	$	299.21
	Nonvested at December 31, 2014		14,858		$	222.81			--
	All nonvested restricted stock units at December 31, 2014 are expected to vest.  The total intrinsic value of all outstanding stock units which were not convertible at December 31, 2014, including 417 stock units held for the accounts of non-employee directors, was $5,194,000.  The total intrinsic value of restricted stock units that vested and were converted during 2014 was $283,000.    The total fair value of directors’ stock units that vested and were converted was $8,000 during each of 2014 and 2013, and $22,000 during 2012.
	Stock awards that vested immediately were awarded under the 2006 Plan to non-employee directors totaling $240,000 in value in 2014 and $120,000 in each of 2013 and 2012.  Compensation related to stock awards, restricted stock and stock units is based on the fair market value of the stock on the date of the grant. These fair values are then amortized on a straight-line basis over the requisite service periods of the entire awards, which is generally the vesting period. Compensation related to stock options is based on the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. For the years ended December 31, 2014, 2013 and 2012, we recorded stock-based compensation expense as a G&A expense in the amount of $2,209,000, $1,586,000 and $1,482,000, respectively, for all of the above mentioned stock-based compensation arrangements. The total tax benefit recognized in the income statement from stock-based compensation arrangements for the years ended December 31, 2014, 2013 and 2012, was $773,000, $555,000 and $516,000, respectively.
	Unrecognized compensation cost information for our various stock-based compensation types is shown below as of December 31, 2014:
		Unrecognized Compensation Cost			Weighted Average
					Remaining Years in Amortization Period
	Stock options	$	767,000			2
	Restricted stock		1,198,000			2.1
	Restricted stock units		1,593,000			3.4
	Total	$	3,558,000
	We have a policy of utilizing treasury shares to satisfy stock option exercises, stock unit conversions and restricted stock awards.

9_Revenues_From_Major_Customer

9. Revenues From Major Customers	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Revenues From Major Customers	We had one major customer which represented approximately $13.5 million (10.2 percent) of our net revenues during 2013.

10_Industry_Segment_and_Geogra

10. Industry Segment and Geographic Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Industry Segment and Geographic Information	We operate in one reportable industry segment: developing and manufacturing products primarily for medical applications and have no foreign operating subsidiaries.  We have other product lines which include pressure relief valves and inflation systems, which are sold primarily to the aviation and marine industries. Due to the similarities in product technologies and manufacturing processes, these products are managed as part of our medical products segment. Our revenues from sales to customers outside the United States totaled approximately 42 percent of our net revenues in each of 2014, 2013 and 2012.  We have no assets located outside the United States.
	A summary of revenues by geographic area, based on shipping destination, for 2014, 2013 and 2012 is as follows (in thousands):
		Year ended December 31,
		2014		2013		2012
	United States	$	81,971	$	75,997	$	69,388
	Canada		11,655		15,114		13,352
	Other countries less than 10% of revenues		47,136		40,882		36,322
	Total	$	140,762	$	131,993	$	119,062
	A summary of revenues by product line for 2014, 2013 and 2012 is as follows (in thousands):
		2014		2013		2012
	Fluid Delivery	$	57,905	$	51,289	$	49,060
	Cardiovascular		43,001		40,182		36,021
	Ophthalmology		19,329		20,736		15,717
	Other		20,527		19,786		18,264
	Total	$	140,762	$	131,993	$	119,062

11_Employee_Retirement_and_Ben

11. Employee Retirement and Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Retirement and Benefit Plans	We sponsor a defined contribution 401(k) plan for all employees. Each participant may contribute certain amounts of eligible compensation. We make a matching contribution to the plan. Our contributions under this plan were $600,000, $561,000 and $533,000 in 2014, 2013 and 2012, respectively.

12_Commitments_and_Contingenci

12. Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	From time to time and in the ordinary course of business, we may be subject to various claims, charges and litigation. In some cases, the claimants may seek damages, as well as other relief, which, if granted, could require significant expenditures. We accrue the estimated costs of settlement or damages when a loss is deemed probable and such costs are estimable, and accrue for legal costs associated with a loss contingency when a loss is probable and such amounts are estimable. Otherwise, these costs are expensed as incurred. If the estimate of a probable loss or defense costs is a range and no amount within the range is more likely, we accrue the minimum amount of the range. As of December 31, 2014, the Company had no ongoing litigation or arbitration for such matters.
	We had a dispute which was favorably settled in the third quarter of 2007. This settlement was amended in December 2008.  The amended settlement agreement provides that we may receive annual payments from 2009 through 2024. We have not recorded $5.0 million in potential future payments under this settlement as of December 31, 2014 due to the uncertainty of payment.
	We have arrangements with three of our executive officers pursuant to which the termination of their employment under certain circumstances would result in lump sum payments to them.  Termination under such circumstances at December 31, 2014 could have resulted in payments aggregating $6.0 million.

13_Quarterly_Financial_Data_Un

13. Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)
	Quarter	Operating		Operating		Net Income		Income		Income
	Ended	Revenue		Income				Per Basic Share		Per Diluted Share
	(In thousands, except per share amounts)
	3/31/14	$	36,419	$	10,700	$	7,201	$	3.63	$	3.61
	6/30/14		35,025		10,257		6,882		3.51		3.48
	9/30/14		36,625		11,226		7,685		3.94		3.91
	12/31/14		32,693		8,632		6,040		3.11		3.08
	3/31/13	$	33,493	$	9,400	$	6,635	$	3.28	$	3.28
	6/30/13		32,605		9,495		6,506		3.23		3.22
	9/30/13		34,044		10,713		7,673		3.82		3.81
	12/31/13		31,851		8,336		5,768		2.88		2.87
	The quarterly information presented above reflects, in the opinion of management, all adjustments necessary for a fair presentation of the results for the interim periods presented.

1_Summary_of_Significant_Accou1

1. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	The consolidated financial statements include the accounts of Atrion Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash equivalents include cash on hand and in the bank as well as money market accounts and debt securities with maturities at the time of purchase of 90 days or less.
	Our investments consist of taxable corporate and United States government agency bonds and equity securities. We classify our investment securities in one of three categories: held-to-maturity, trading, or available-for-sale. Securities that we have the positive intent and ability to hold to maturity are reported at amortized cost and classified as held-to-maturity securities.  If we do not have the intent and ability to hold a security to maturity, we report the investment as available-for-sale securities.  We report available-for-sale securities at fair value with unrealized gains and, to the extent deemed temporary, unrealized losses recorded in stockholders’ equity as accumulated other comprehensive loss.  We consider investments which will mature in the next 12 months as current assets. The remaining investments are considered non-current assets including our investment in equity securities which we intend to hold longer than 12 months. We periodically evaluate our investments for impairment. We do not believe any unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence as of December 31, 2014.
	The components of the Company’s cash and cash equivalents and our short and long-term investments as of December 31, 2014 and 2013 are as follows (in thousands):
		2014		2013
	Cash and cash equivalents::
	Cash deposits	$	14,572	$	25,958
	Money market funds		6,203		2,601
	Total cash and cash equivalents	$	20,775	$	28,559
	Short-term investments:
	Corporate bonds (held-to-maturity)	$	3,084	$	18,351
	Total short-term investments	$	3,084	$	18,351
	Long-term investments:
	Corporate bonds (held-to-maturity)	$	10,028	$	10,069
	US government agency bonds (held-to-maturity)		8,400		--
	Equity securities (available-for-sale)		3,332		--
	Total long term investments	$	21,760	$	10,069
	Total cash, cash equivalents and short and long-term investments	$	45,619	$	56,979
Trade Receivables	Trade accounts receivable are recorded at the original sales price to the customer.  We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments.  On an ongoing basis, the collectability of accounts receivable is assessed based upon historical collection trends, current economic factors and the assessment of the collectability of specific accounts.  We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with appropriate Company personnel and with the customers directly.  Accounts are written off when we determine the receivable will not be collected.
Inventories	Inventories are stated at the lower of cost (including materials, direct labor and applicable overhead) or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventory (in thousands):
		December 31,
		2014		2013
	Raw materials	$	12,575	$	10,744
	Work in process		5,600		6,246
	Finished goods		9,847		9,276
	Total inventories	$	28,022	$	26,266
Accounts Payable	We reflect disbursements as trade accounts payable until such time as payments are presented to our bank for payment. At December 31, 2014 and 2013, disbursements totaling approximately $613,000 and $443,000, respectively, had not been presented for payment to our bank.
Income Taxes	We account for income taxes utilizing Accounting Standards Codification (ASC) 740, Income Taxes , or ASC 740.  ASC 740 requires the asset and liability method for the recording of deferred income taxes, whereby deferred tax assets and liabilities are recognized based on the tax effects of temporary differences between the financial statement and the tax bases of assets and liabilities, as measured at current enacted tax rates. When appropriate, we evaluate the need for a valuation allowance to reduce deferred tax assets.
	ASC 740 also requires the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attributes of income tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more-likely-than-not of being sustained.
	Our uncertain tax positions are recorded as “Other non-current liabilities.” We classify interest expense on underpayments of income taxes and accrued penalties related to unrecognized tax benefits in the income tax provision.
Property Plant and Equipment	Property, plant and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Additions and improvements are capitalized, including all material, labor and engineering costs to design, install or improve the asset. Expenditures for repairs and maintenance are charged to expense as incurred. The following table represents a summary of property, plant and equipment at original cost (in thousands):
		December 31,				Useful
		2014		2013		Lives
	Land	$	5,260	$	5,260		—
	Buildings		31,751		31,314	30-40 yrs
	Machinery and equipment		105,160		93,930	3-15 yrs
	Total property, plant and equipment	$	142,171	$	130,504
	Depreciation expense of $8,454,000, $8,413,000 and $7,448,000 was recorded for the years ended December 31, 2014, 2013 and 2012, respectively. Depreciation expense is recorded in either cost of goods sold or operating expenses based on the associated assets’ usage.
Patents and Licenses	Costs for patents and licenses acquired are determined at acquisition date. Patents and licenses are amortized over the useful lives of the individual patents and licenses, which are from 7 to 20 years. Patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.
Goodwill	Goodwill represents the excess of cost over the fair value of tangible and identifiable intangible net assets acquired.  Annual impairment testing for goodwill is done using a qualitative assessment on goodwill impairment to determine whether it is necessary to perform the two-step goodwill impairment test.  Goodwill is also reviewed whenever events or changes in circumstances indicate a change in value may have occurred.  We have identified three reporting units where goodwill was recorded for purposes of testing goodwill impairment annually: (1) Atrion Medical Products, Inc., (2) Halkey-Roberts Corporation and (3) Quest Medical, Inc.  The total carrying amount of goodwill in each of the years ended December 31, 2014, 2013 and 2012 was $9,730,000. Our evaluation of goodwill during each year resulted in no impairment losses.
Current Accrued Liabilities	The items comprising current accrued liabilities are as follows (in thousands):
		December 31,
		2014		2013
	Accrued payroll and related expenses	$	4,240	$	3,711
	Accrued vacation		219		229
	Other accrued liabilities		491		483
	Total accrued liabilities	$	4,950	$	4,423
Revenues	We recognize revenue when our products are shipped to our customers, provided an arrangement exists, the fee is fixed and determinable and collectability is reasonably assured. All risks and rewards of ownership pass to the customer upon shipment. Net sales represent gross sales invoiced to customers, less certain related charges, including discounts, returns and other allowances. Revenues are recorded exclusive of sales and similar taxes. Returns, discounts and other allowances have been insignificant historically.
Shipping and Handling Policy	Shipping and handling fees charged to customers are reported as revenue and all shipping and handling costs incurred related to products sold are reported as cost of goods sold.
Research and Development Costs	Research and development costs relating to the development of new products and improvements of existing products are expensed as incurred.
Stock-Based Compensation	We have stock-based compensation plans covering certain of our officers, directors and key employees. As explained in detail in Note 8, we account for stock-based compensation utilizing the fair value recognition provisions of ASC 718, Compensation-Stock Compensation, or ASC 718.
New Accounting Pronouncements	From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board, or FASB, or other standards setting bodies, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.
Fair Value Measurements	Accounting standards use a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists therefore requiring an entity to develop its own assumptions.
	As of December 31, 2014 and 2013, we held certain investments in corporate and government debt securities as well as certain equity securities. These investments are all considered Level 2 assets and the fair value of our investments were estimated using recently executed transactions and market price quotations (see Note 2).
	The carrying values of our other financial instruments including cash and cash equivalents, money market accounts, accounts receivable, accounts payable, accrued liabilities, and accrued income and other taxes approximated fair value due to their liquid and short-term nature.
Concentration of Credit Risk	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable.
	Our cash and cash equivalents are held in accounts with financial institutions that we believe are creditworthy. Certain of these amounts at times may exceed federally-insured limits. At December 31, 2014, approximately 91% of our cash and cash equivalents were uninsured. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds.
	We have investments in United States government agency securities and corporate bonds. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer and otherwise. Approximately 24% of our aggregate fixed-income investments are below investment grade. These securities have a higher degree of credit or default risk and a greater exposure to credit risk and may be less liquid in times of economic weakness or market disruptions.
	For accounts receivable, we perform ongoing credit evaluations of our customers’ financial condition and generally do not require collateral.  We maintain reserves for possible credit losses.  As of December 31, 2014 and 2013, we had allowances for doubtful accounts of approximately $22,000 and $86,000, respectively.  The carrying amount of the receivables approximates their fair value. Our customer that generates our largest revenues accounted for 6.5%, 8.2% and 16.3% of accounts receivable as of December 31, 2014, 2013 and 2012, respectively.  No other customer exceeded 10% of our accounts receivable as of December 31, 2014, 2013 or 2012.

1_Summary_of_Significant_Accou2

1. Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Components of the Company's cash and cash equivalents and our short and long-term investments		2014		2013
	Cash and cash equivalents::
	Cash deposits	$	14,572	$	25,958
	Money market funds		6,203		2,601
	Total cash and cash equivalents	$	20,775	$	28,559
	Short-term investments:
	Corporate bonds (held-to-maturity)	$	3,084	$	18,351
	Total short-term investments	$	3,084	$	18,351
	Long-term investments:
	Corporate bonds (held-to-maturity)	$	10,028	$	10,069
	US government agency bonds (held-to-maturity)		8,400		--
	Equity securities (available-for-sale)		3,332		--
	Total long term investments	$	21,760	$	10,069
	Total cash, cash equivalents and short and long-term investments	$	45,619	$	56,979
Major Components of Inventories		December 31,
		2014		2013
	Raw materials	$	12,575	$	10,744
	Work in process		5,600		6,246
	Finished goods		9,847		9,276
	Total inventories	$	28,022	$	26,266
Summary of Property Plant and Equipment at Original Cost		December 31,				Useful
		2014		2013		Lives
	Land	$	5,260	$	5,260		—
	Buildings		31,751		31,314	30-40 yrs
	Machinery and equipment		105,160		93,930	3-15 yrs
	Total property, plant and equipment	$	142,171	$	130,504
Current Accrued Liabilities		December 31,
		2014		2013
	Accrued payroll and related expenses	$	4,240	$	3,711
	Accrued vacation		219		229
	Other accrued liabilities		491		483
	Total accrued liabilities	$	4,950	$	4,423

2_Investments_Tables

2. Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Investments, Held-to-Maturity Securities				Gross Unrealized
		Cost		Gains		Losses			Fair value
	As of December 31, 2014:
	Short-term Investments:
	Corporate bonds	$	3,084	$	--	$	(6	)	$	3,078
	Long-term Investments:
	Corporate and government bonds	$	18,428	$	21	$	(292	)	$	18,157
	As of December 31, 2013:
	Short-term Investments:
	Corporate bonds	$	18,351	$	234	$	—		$	18,585
	Long-term Investments:
	Corporate bonds	$	10,069	$	285	$	—		$	10,354
Investments, Available for sale				Gross Unrealized
		Cost		Gains		Losses			Fair value
	As of December 31, 2014:
	Long-term Investments:
	Equity investments	$	3,708	$	--	$	(376	)	$	3,332

3_Patents_and_Licenses_Tables

3. Patents and Licenses (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Information Regarding Patents and Licenses	31-Dec-14								31-Dec-13
	Weighted Average				Gross				Weighted Average		Gross
	Original Life				Carrying		Accumulated		Original Life		Carrying		Accumulated
	(years)				Amount		Amortization		(years)		Amount		Amortization
		15.67			$	13,840	$	11,302		15.67	$	13,840	$	11,032
Estimated Future Amortization Expense	2015		$	269
	2016		$	269
	2017		$	173
	2018		$	141
	2019		$	141

5_Income_Taxes_Tables

5. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Expense				Year ended December 31,
				2014				2013				2012
	Current	— Federal		$	12,626			$	12,541			$	8,934
		— State			1,585				1,065				1,050
					14,211				13,606				9,984
	Deferred	— Federal			31				(1,063	)			1,363
		— State			(29	)			140				99
					2				(923	)			1,462
	Total income tax expense			$	14,213			$	12,683			$	11,446
Deferred Income Tax Assets and Liabilities with Temporary Differences and Carryforwards			2014				2013
	Deferred tax assets:
	Benefit plans		$	1,535			$	1,590
	Inventories			483				525
	Other			158				37
	Total deferred tax assets		$	2,176			$	2,152
	Deferred tax liabilities:
	Property, plant and equipment		$	9,648			$	9,716
	Patents and goodwill			2,926				2,956
	Other			158				166
	Total deferred tax liabilities		$	12,732			$	12,838
	Net deferred tax liability		$	10,556			$	10,686
	Balance Sheet classification:
	Non-current deferred income tax liability		$	11,129			$	12,062
	Current deferred income tax asset			573				1,376
	Net deferred tax liability		$	10,556			$	10,686
Illustration of Total Income Tax Expense Difference with Amount Provided by Applying Statutory Federal Income Tax Rate to Pretax Earnings			Year ended December 31,
			2014				2013				2012
	Income tax expense at the statutory federal income tax rate		$	14,707			$	13,743			$	12,276
	Increase (decrease) resulting from:
	State income taxes			934				770				747
	Section 199 manufacturing deduction			(1,290	)			(1,307	)			(949	)
	Other, net			(138	)			(523	)			(628	)
	Total income tax expense		$	14,213			$	12,683			$	11,446
Reconciliation of Beginning and Ending Balances of Total Amounts of Gross Unrecognized Tax Benefits	Gross unrecognized tax benefits at January 1, 2012		$	1,261
	Increase in tax positions for prior years			19
	Increase in tax positions for current year			0
	Decrease due to settlement with taxing authorities			(641	)
	Lapse in statutes of limitation			(98	)
	Gross unrecognized tax benefits at December 31, 2012		$	541
	Increase in tax positions for prior years			11
	Increase in tax positions for current year			0
	Lapse in statutes of limitation			(206	)
	Gross unrecognized tax benefits at December 31, 2013		$	346
	Increase in tax positions for prior years			6
	Increase in tax positions for current year			0
	Lapse in statutes of limitation			(223	)
	Gross unrecognized tax benefits at December 31, 2014		$	129

7_Income_Per_Share_Tables

7. Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Computation of Basic and Diluted Income Per Share		Year ended December 31,
		2014		2013		2012
		(In thousands, except per share amounts)
	Net Income	$	27,808	$	26,582	$	23,629
	Weighted average basic shares outstanding		1,958		2,010		2,016
	Add:  Effect of dilutive securities		17		7		11
	Weighted average diluted shares outstanding		1,975		2,017		2,027
	Net Income per share
	Basic	$	14.2	$	13.22	$	11.72
	Diluted	$	14.08	$	13.18	$	11.66

8_Stock_Plans_Tables

8. Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Compensation Related Costs [Abstract]
Option Transaction	Options	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term
	Outstanding at December 31, 2013		50,000		$	204.76
	Granted		--			--
	Exercised		--			--
	Outstanding at December 31, 2014		50,000		$	204.76	3.9 years
	Exercisable at December 31, 2014		25,000		$	200.1	3.8 years
Black-Scholes Option Pricing Model Weighted Average Assumptions		2014			2013			2012
	Risk-free interest rate		--			--			0.5	%
	Dividend yield		--			--			1	%
	Volatility factor		--			--			25	%
	Expected life		--			--		5 years
Restricted Stock Activity	Nonvested Shares	Shares			Weighted Average Award Date Fair Value Per Share
	Restricted stock at December 31, 2013		10,500		$	208.09
	Granted in 2014		1,400		$	315.24
	Vested in 2014		(4,400	)	$	239.91
	Restricted stock at December 31, 2014		7,500		$	209.42
Changes in Stock Units	Nonvested Stock Units	Restricted Stock Units			Weighted Average Award Date Fair Value Per Unit			Director’s Stock Units			Weighted Average Award Date Fair Value Per Unit
	Nonvested at December 31, 2013		12,904		$	196.35			--
	Granted		2,785		$	316.55			28		$	299.21
	Vested		(831	)	$	126.18			(28	)	$	299.21
	Nonvested at December 31, 2014		14,858		$	222.81			--
Unrecognized Compensation Cost		Unrecognized Compensation Cost			Weighted Average
					Remaining Years in Amortization Period
	Stock options	$	767,000			2
	Restricted stock		1,198,000			2.1
	Restricted stock units		1,593,000			3.4
	Total	$	3,558,000

10_Industry_Segment_and_Geogra1

10. Industry Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Revenues by Geographic Territory		Year ended December 31,
		2014		2013		2012
	United States	$	81,971	$	75,997	$	69,388
	Canada		11,655		15,114		13,352
	Other countries less than 10% of revenues		47,136		40,882		36,322
	Total	$	140,762	$	131,993	$	119,062
Revenue by Product Line		2014		2013		2012
	Fluid Delivery	$	57,905	$	51,289	$	49,060
	Cardiovascular		43,001		40,182		36,021
	Ophthalmology		19,329		20,736		15,717
	Other		20,527		19,786		18,264
	Total	$	140,762	$	131,993	$	119,062

13_Quarterly_Financial_Data_Un1

13. Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	Quarter	Operating		Operating		Net Income		Income		Income
	Ended	Revenue		Income				Per Basic Share		Per Diluted Share
	(In thousands, except per share amounts)
	3/31/14	$	36,419	$	10,700	$	7,201	$	3.63	$	3.61
	6/30/14		35,025		10,257		6,882		3.51		3.48
	9/30/14		36,625		11,226		7,685		3.94		3.91
	12/31/14		32,693		8,632		6,040		3.11		3.08
	3/31/13	$	33,493	$	9,400	$	6,635	$	3.28	$	3.28
	6/30/13		32,605		9,495		6,506		3.23		3.22
	9/30/13		34,044		10,713		7,673		3.82		3.81
	12/31/13		31,851		8,336		5,768		2.88		2.87

1_Summary_of_Significant_Accou3

1. Summary of Significant Accounting Policies (Details - Cash and cash equivalents and short and long-term investments) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Cash deposits	$14,572	$25,958
Money market funds	6,203	2,601
Total cash and cash equivalents	20,775	28,559	7,999	24,590
Short-term investments:
Corporate bonds (held-to-maturity)	3,084	18,351
Total short-term investments	3,084	18,351
Long-term investments:
Equity securities (available for sale)	3,332	0
Total long term investments	21,760	10,069
Total cash, cash equivalents and short and long-term investments	45,619	56,979
Corporate Bond Securities [Member]
Long-term investments:
Held-to-maturity	10,028	10,069
US government agency bonds
Long-term investments:
Held-to-maturity	$8,400	$0

1_Summary_of_Significant_Accou4

1. Summary of Significant Accounting Policies (Detail - Major Components of Inventories) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$12,575	$10,744
Work in process	5,600	6,246
Finished goods	9,847	9,276
Total inventories	$28,022	$26,266

1_Summary_of_Significant_Accou5

1. Summary of Significant Accounting Policies (Detail - Property Plant and Equipment) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Land	5,260	$5,260
Buildings	31,751	31,314
Machinery and equipment	105,160	93,930
Total property, plant and equipment	142,171	$130,504
Machinery And Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful lives	15 years
Machinery And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful lives	3 years
Building And Building Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful lives	40 years
Building And Building Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful lives	30 years

1_Summary_of_Significant_Accou6

1. Summary of Significant Accounting Policies (Detail - Current Accrued Liabilities) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued payroll and related expenses	$4,240	$3,711
Accrued vacation	219	229
Other accrued liabilities	491	483
Total accrued liabilities	$4,950	$4,423

1_Summary_of_Significant_Accou7

1. Summary of Significant Accounting Policies (Detail Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]
Depreciation expense	$8,454	$8,413	$7,448
Goodwill, carrying amount	9,730	9,730	9,730
Goodwill, impairment loss	0	0	0
Allowances for doubtful accounts	$22	$86
Cash deposits in excess of federally insured limits
Significant Accounting Policies [Line Items]
Risk concentration	91.00%
Accounts Receivable [Member] | Major Customer [Member]
Significant Accounting Policies [Line Items]
Risk concentration	6.50%	16.30%	8.20%
Patent And License [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Patents and licenses, useful lives	7 years
Patent And License [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Patents and licenses, useful lives	20 years

2_Investments_Detail_HeldtoMat

2. Investments (Detail - Held-to-Maturity Securities) (Corporate Bond Securities [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Short Term Investments [Member]
Schedule of Held-to-maturity Securities [Line Items]
Cost	$3,084	$18,351
Gross Unrealized Gains	0	234
Gross Unrealized Losses	-6	0
Fair Value	3,078	18,585
Long Term Investments [Member]
Schedule of Held-to-maturity Securities [Line Items]
Cost	18,428	10,069
Gross Unrealized Gains	21	285
Gross Unrealized Losses	-292	0
Fair Value	$18,157	$10,354

2_Investments_Details_Availabl

2. Investments (Details - Available-for sale-securities) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Investments Details - Available-For Sale-Securities
Equity investment, cost	$3,708
Equity investments, unrealized gains	0
Equity investments, unrealized losses	-376
Equity investments, fair value	$3,332	$0

2_Investments_Detail_Narrative

2. Investments (Detail Narrative)	12 Months Ended
	Dec. 31, 2014
Maximum [Member]
Schedule of Investments [Line Items]
Securities maturity length	3 months 15 days
Minimum [Member]
Schedule of Investments [Line Items]
Securities maturity length	58 months

3_Patents_and_Licenses_Details

3. Patents and Licenses (Details - Purchased patents and licenses) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$11,301	$11,032
Patent And License [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Original Life (years)	15 years 8 months 8 days	15 years 8 months 8 days
Gross Carrying Amount	13,840	13,840
Accumulated Amortization	$11,302	$11,032

3_Patents_and_Licenses_Details1

3. Patents and Licenses (Details Narrative) (Patent And License [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Patent And License [Member]
Finite-Lived Intangible Assets [Line Items]
Aggregate amortization expense	$269	$179	$162

3_Patents_and_LicensesDetails_

3. Patents and Licenses(Details - Estimated Future Amortization Expense) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$269
2016	269
2017	173
2018	141
2019	$141

4_Line_of_Credit_Details_Narra

4. Line of Credit (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Debt Disclosure [Abstract]
Revolving line of credit, maximum principal amount	$4,000,000
Line of credit	$0
Revolving line of credit, interest plus LIBOR	1.16%	[1]
Term loan, maturity period	2 years
[1]	LIBOR plus 1.16 percent

5_Income_Taxes_Details_Income_

5. Income Taxes (Details - Income tax expense items) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal income tax, current	$12,626	$12,541	$8,934
State income tax, current	1,585	1,065	1,050
Income tax, current	14,211	13,606	9,984
Federal income tax, deferred	31	-1,063	1,363
State income tax, deferred	-29	140	99
Income tax, deferred	2	-923	1,462
Total income tax expense	$14,213	$12,683	$11,446

5_Income_Taxes_Details_Deferre

5. Income Taxes (Details - Deferred Income Tax Assets and Liabilities) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Benefit plans	$1,535	$1,590
Inventories	483	525
Other	158	37
Total deferred tax assets	2,176	2,152
Deferred tax liabilities:
Property, plant and equipment	9,648	9,716
Patents and goodwill	2,926	2,956
Other	158	166
Total deferred tax liabilities	12,732	12,838
Net deferred tax liability	10,556	10,686
Balance Sheet classification:
Non-current deferred income tax liability	11,129	12,062
Current deferred income tax asset	573	1,376
Net deferred tax liability	$10,556	$10,686

5_Income_Taxes_Details_Reconci

5. Income Taxes (Details - Reconciliation) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Income tax expense at the statutory federal income tax rate	$14,707	$13,743	$12,276
Increase (decrease) resulting from:
State income taxes	934	770	747
Section 199 manufacturing deduction	-1,290	-1,307	-949
Other, net	-138	-523	-628
Total income tax expense	$14,213	$12,683	$11,446

5_Income_Taxes_Details_Gross_U

5. Income Taxes (Details - Gross Unrecognized Tax Benefits) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits beginning balance	$346	$541	$1,261
Increase in tax positions for prior years	6	11	19
Increase in tax positions for current year	0	0	0
Decrease due to settlement with taxing authorities			-641
Lapse in statutes of limitation	-223	-206	-98
Gross unrecognized tax benefits ending balance	$129	$346	$541

5_Income_Taxes_Details_Narrati

5. Income Taxes (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, reduced			$641
Unrecognized tax benefits, accrued interest	9	21	26
Unrecognized tax benefits, net interest benefit	$12	$51	$5	[1]
[1]	5.4

6_Stockholders_Equity_Details_

6. Stockholders’ Equity (Details Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders Equity Details Narrative
Stock repurchase program, shares authorized to be repurchased	200,000
Stock repurchase program, shares remained eligible for repurchase	54,026
Stock repurchase program, number of shares repurchased	74,746	36,666	26,562

7_Income_Per_Share_Details_Bas

7. Income Per Share (Details - Basic and diluted) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Net Income	$6,040	$7,685	$6,882	$7,201	$5,768	$7,673	$6,506	$6,635	$27,808	$26,582	$23,629
Weighted Average Basic Shares Outstanding									1,958	2,010	2,016
Add: Effect of dilutive securities									17	7	11
Weighted average diluted shares outstanding									1,975	2,017	2,027
Net Income per share
Basic	$3.11	$3.94	$3.51	$3.63	$2.88	$3.82	$3.23	$3.28	$14.20	$13.22	$11.72
Diluted	$3.08	$3.91	$3.48	$3.61	$2.87	$3.81	$3.22	$3.28	$14.08	$13.18	$11.66

7_Income_per_Share_Detail_Narr

7. Income per Share (Detail Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Anti-dilutive shares excluded from computation of diluted shares	8	4,344

8_Stock_Plans_Details_Stock_Op

8. Stock Plans (Details - Stock Option Transactions) (USD $)	12 Months Ended
	Dec. 31, 2014
Shares
Outstanding at December 31, 2013	50,000
Granted	0
Exercised	0
Outstanding at December 31, 2014	50,000
Exercisable at December 31, 2014	25,000
Weighted Average, Exercise Price
Outstanding at December 31, 2013	$204.76
Outstanding at December 31, 2014	$204.76
Exercisable at December 31, 2014	$200.10
Weighted Average Remaining Contractual Term
Outstanding at December 31, 2014	3 years 10 months 24 days
Exercisable at December 31, 2014	3 years 9 months 18 days

8_Stock_Plans_Details_BlackSch

8. Stock Plans (Details - Black-Scholes Option Pricing Model Weighted Average Assumptions)	12 Months Ended
	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	0.50%
Dividend yield	1.00%
Volatility factor	25.00%
Expected life	5 years

8_Stock_Plans_Details_Restrict

8. Stock Plans (Details - Restricted Stock Activity) (USD $)	12 Months Ended
	Dec. 31, 2014
Restricted Stock Units R S U [Member]
Shares
Beginning Balance	12,904
Granted	2,785
Vested	-831
Ending Balance	14,858
Weighted Average Award Date Fair Value Per Share
Beginning Balance	$196.35
Granted	$316.55
Vested	$126.18
Ending Balance	$222.81
Restricted Stock Units R S U [Member] | Non Employee Director [Member]
Shares
Beginning Balance	0
Granted	28
Vested	-28
Ending Balance	0
Weighted Average Award Date Fair Value Per Share
Granted	$299.21
Vested	$299.21
Restricted Stock [Member]
Shares
Beginning Balance	10,500
Granted	1,400
Vested	-4,400
Ending Balance	7,500
Weighted Average Award Date Fair Value Per Share
Beginning Balance	$208.09
Granted	$315.24
Vested	$239.91
Ending Balance	$209.42

8_Stock_Plans_Details_Unrecogn

8. Stock Plans (Details - Unrecognized Compensation Cost ) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Cost, stock options	$767
Total Unrecognized Compensation Cost	3,558
Restricted Stock Units R S U [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Cost, other than options	1,593
Weighted Average Remaining Years in Amortization Period	3 years 4 months 24 days
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Years in Amortization Period	2 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Cost, other than options	$1,198
Weighted Average Remaining Years in Amortization Period	2 years 1 month 6 days

8_Stock_Plans_Details_Narrativ

8. Stock Plans (Details Narrative) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation plan, total intrinsic values of options outstanding	$6,800
Stock compensation plan, total intrinsic values of options exercisable	3,500
Fair value restricted stock awards vested	1,372	633	559
Stock compensation plan, total intrinsic value of unvested restricted stock	5,194
Stock-based compensation expense	2,209	1,586	1,482
Stock-based compensation expense, total tax benefit recognized	773	555	516
General And Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$2,209	$1,586	$1,482
2006 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation plan, remaining number of common stock shares reserved	52,751
Deferred Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation plan, remaining number of common stock shares reserved	1,599
Director Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation plan, remaining number of common stock shares reserved	1,126

Recovered_Sheet1

9. Revenues from Major Customers (Details Narrative) (Sales [Member], Major Customer [Member])	12 Months Ended
	Dec. 31, 2013
Sales [Member] | Major Customer [Member]
Concentration Risk [Line Items]
Percentage of net revenue	10.20%	[1]
[1]	Approximately $13.5 million

10_Industry_Segment_and_Geogra2

10. Industry Segment and Geographic Information (Details - Geographic area) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues	$32,693	$36,625	$35,025	$36,419	$31,851	$34,044	$32,605	$33,493	$140,762	$131,993	$119,062
U S
Segment Reporting Information [Line Items]
Revenues									81,971	75,997	69,388
Canada
Segment Reporting Information [Line Items]
Revenues									11,655	15,114	13,352
Other Countries [Member]
Segment Reporting Information [Line Items]
Revenues									$47,136	$40,882	$36,322

10_Industry_Segment_and_Geogra3

10. Industry Segment and Geographic Information (Details - Revenues by product line ) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue from External Customer [Line Items]
Revenues	$32,693	$36,625	$35,025	$36,419	$31,851	$34,044	$32,605	$33,493	$140,762	$131,993	$119,062
Fluid Delivery [Member]
Revenue from External Customer [Line Items]
Revenues									57,905	51,289	49,060
Cardiovascular [Member]
Revenue from External Customer [Line Items]
Revenues									43,001	40,182	36,021
Ophthalmology [Member]
Revenue from External Customer [Line Items]
Revenues									19,329	20,736	15,717
Other Products [Member]
Revenue from External Customer [Line Items]
Revenues									$20,527	$19,786	$18,264

10_Industry_Segment_and_Geogra4

10. Industry Segment and Geographic Information (Detail) (Geographic Concentration Risk [Member], Sales [Member], Outside United States [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Geographic Concentration Risk [Member] | Sales [Member] | Outside United States [Member]
Segment Reporting Information [Line Items]
Percentage of revenues	42.00%	42.00%	42.00%

11_Employee_Retirement_and_Ben1

11. Employee Retirement and Benefit Plans (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Defined contribution plan, employer contribution	$600	$561	$533

12_Commitments_and_Contingenci1

12. Commitments and Contingencies (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
Gain contingency, potential future payment receivable under settlement	$5,000
Loss contingency, estimated payment from termination of executive officers	$6,000

13_Quarterly_Financial_Data_De

13. Quarterly Financial Data (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Operating Revenue	$32,693	$36,625	$35,025	$36,419	$31,851	$34,044	$32,605	$33,493	$140,762	$131,993	$119,062
Operating Income	8,632	11,226	10,257	10,700	8,336	10,713	9,495	9,400	40,817	37,944	33,626
Net Income	$6,040	$7,685	$6,882	$7,201	$5,768	$7,673	$6,506	$6,635	$27,808	$26,582	$23,629
Income Per Basic Share	$3.11	$3.94	$3.51	$3.63	$2.88	$3.82	$3.23	$3.28	$14.20	$13.22	$11.72
Income Per Diluted Share	$3.08	$3.91	$3.48	$3.61	$2.87	$3.81	$3.22	$3.28	$14.08	$13.18	$11.66